Catalog #
  • ---All---
  • Uniprot Id
  • Catalog #

VEGFC antibody ( Ascites)

Mouse Monoclonal Antibody (Mab)

Country
United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanKoreaLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamOthers
Ordering Information
Catalog # SizeAvailability Price  
AM1886a 0.1 ml In Stock
$ 265.00email & fax$ 251.75online
Add to cart
  • Specification
  • Citations : 0
  • Reviews
  • Protocols
  • Background

VEGFC antibody ( Ascites) - Product Information

Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB
Primary AccessionP49767
ReactivityHuman
Isotype IgG1,IGK
Clone Names197CT7.3.4
Calculated MW 46883 Da

VEGFC antibody ( Ascites) - Additional Information

Gene ID 7424
Other Names
VEGFC; Vascular endothelial growth factor C; Flt4 ligand; Vascular endothelial growth factor-related protein
Target/Specificity
This VEGFC monoclonal antibody is generated from mouse immunized with VEGFC recombinant protein.
Dilution
WB~~1:1000~8000
Format
Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
VEGFC antibody ( Ascites) is for research use only and not for use in diagnostic or therapeutic procedures.

VEGFC antibody ( Ascites) - Protein Information

Name VEGFC
Function
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
Cellular Location
Secreted.
Tissue Location
Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte

VEGFC antibody ( Ascites) - Related Products

AM1100A: VEGF3 Antibody

AM1886b: VEGFC Antibody

AP11951A: VEGF3 Antibody (N-term)

AP2042C: VEGFC (VEGF3) Antibody (Center M263)

BP11951a: VEGF3 Antibody (N-term) Blocking Peptides

BP2042c: VEGF3 Antibody (Center M263) Blocking Peptide

VEGFC antibody ( Ascites) - Research Areas

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D. [provided by RefSeq].

REFERENCES

Chen, X., et al. Cancer Sci. 101(11):2384-2390(2010)
Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Deguchi, K., et al. Anticancer Res. 30(6):2361-2366(2010)
Johnatty, S.E., et al. PLoS Genet. 6 (7), E1001016 (2010) :